Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant

Rhea-AI Filing Summary

Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.

MYRIAD GENETICS INC director Heinrich Dreismann received a grant of 59,701 restricted stock units of common stock. The award was made at no cash cost per share and is part of the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a right to receive one common share and will vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Following this equity award, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dreismann Heinrich

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	59,701	$0.00	--

Holdings After Transaction: Common Stock — 231,145 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 59,701 shares Grant price per share: $0.00 per share Shares held after grant: 231,145 shares

3 metrics

RSU grant size 59,701 shares Restricted stock units of common stock granted to director

Grant price per share $0.00 per share Reported transaction price for the RSU award

Shares held after grant 231,145 shares Director’s direct common stock holdings following transaction

Key Terms

restricted stock units, Equity Incentive Plan, vests, contingent right

4 terms

restricted stock units financial

"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vests financial

"and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting"

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dreismann Heinrich

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		59,701(1)	A	$0	231,145	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

Remarks:

	By: Justin Hunter For: Heinrich Dreismann	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MYRIAD GENETICS (MYGN) report for Heinrich Dreismann?

MYRIAD GENETICS reported that director Heinrich Dreismann received 59,701 restricted stock units of common stock as an equity award. The grant was recorded at a price of $0.00 per share and increased his direct holdings to 231,145 common shares after the transaction.

What type of shares did Heinrich Dreismann acquire in the MYGN Form 4 filing?

Heinrich Dreismann acquired restricted stock units that each represent a contingent right to receive one share of MYRIAD GENETICS common stock. These units were granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan as part of his director compensation package.

When do Heinrich Dreismann’s MYGN restricted stock units vest?

The restricted stock units vest upon the earlier of two events: the first anniversary of the grant date or the date of the next annual meeting of stockholders. This time-based vesting schedule aligns the director’s equity award with the company’s governance calendar.

How many MYGN shares does Heinrich Dreismann hold after this Form 4 transaction?

After the reported equity grant, Heinrich Dreismann directly holds 231,145 shares of MYRIAD GENETICS common stock. This figure includes the impact of the 59,701 restricted stock units awarded in the transaction, which are structured to settle one-for-one into common shares upon vesting.

Was the MYGN equity grant to Heinrich Dreismann an open-market purchase or compensation award?

The transaction was a compensation-related equity award, not an open-market purchase. The Form 4 uses transaction code “A” for a grant or award, and the reported price per share is $0.00, indicating stock-based compensation rather than a cash-funded market trade.